BioBalance Corp. (BioBalance), a wholly owned subsidiary of New York Health Care, Inc.(OTC BB: BBAL), announced today the acceptance of a scientific abstract submitted for presentation at the Digestive Disease Week (DDW) conference to be held in Los Angeles, CA, May 20-25, 2006, at the Los Angeles Convention Center. The abstract highlights new scientific findings regarding Probactrix®, BioBalance’s patented strain of the biotherapeutic agent E.coli M-17.
